J. Ljubimova
Molecular Biology · 2011–2016
A researcher in the Science corpus: 3 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 64 citations into it
- Biomaterials — 24 citations into it
Whom J. Ljubimova trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Theresa M. Allen (in Biomaterials)
- P. Cullis (in Molecular Biology)
Papers from J. Ljubimova's perspective
Ordered by how strongly the researchers J. Ljubimova trusts endorse each paper. Same corpus, a different order for every researcher.
- Prospective identification of tumorigenic breast cancer cells (Proceedings of the National Academy of Sciences of the United States of America)
- Hallmarks of cancer: the next generation. (Cell)
- Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity (Nature Immunology)
- Stem cells, cancer, and cancer stem cells (Nature)
- Identification of human brain tumour initiating cells (Nature)
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing (New England Journal of Medicine)
- EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. (Proceedings of the National Academy of Sciences of the United States of America)
- A human colon cancer cell capable of initiating tumour growth in immunodeficient mice (Nature)
- Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. (Cancer Research)
- EXPRESSION OF UBIQUITIN-SPECIFIC PROTEASE 14 IN HUMAN PANCREATIC CANCER CELL LINES AND CANCER TISSUES
Their papers
- Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma (2016) — 1,926 citations
- Nanomedicine therapeutic approaches to overcome cancer drug resistance (2013) — 675 citations
- Transferrin receptors and the targeted delivery of therapeutic agents against cancer (2011) — 729 citations